CAS: 1421373-65-0 AZD-9291
CAS No.: 1421373-65-0
Purity: 97% Min.
Package: 5 g / 25 g / 100 g
Delivery: DHL/FEDEX/UPS or By sea
- Worldwide Delivery
- Quality Assurance
- 24/7 Customer Service
Product Introduction
Introduction
Osimertinib (previously known as mereletinib or AZD9291; trade name Tagrisso) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals – for mutated EGFR cancers.
Specification of CAS: 1421373-65-0 AZD-9291
ITEMS | SPECIFICATION |
CAS DataBase Reference | 1421373-65-0 |
pka | 12.68±0.70(Predicted) |
density | 1.19±0.1 g/cm3(Predicted) |
Related articles of CAS: 1421373-65-0 AZD-9291
SHR‐A1403, a novel c‐mesenchymal‐epithelial transition factor (c‐Met) antibody‐drug conjugate, overcomes AZD 9291 resistance in non‐small cell lung cancer cells …
M Tong, M Gao, Y Xu, L Fu, Y Li, X Bao, H Fu… - Cancer …, 2019 - Wiley Online Library
A case report of toxic epidermal necrolysis associated with AZD-9291
J Wang, XY Cheng, Y Lu, BR Zhou - Drug Design, Development …, 2018 - ncbi.nlm.nih.gov
Hot Tags: cas: 1421373-65-0 azd-9291, price, quotation, discount, in stock, for sale, Life Science
